Insulin glargine biosimilar - Gan & Lee Pharmaceuticals

Drug Profile

Insulin glargine biosimilar - Gan & Lee Pharmaceuticals

Alternative Names: Basalin

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Gan&Lee Pharmaceuticals
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Insulin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus
  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 01 Sep 2016 Gan and Lee Pharmaceuticals completes a phase-I trial in Type-1 diabetes mellitus in USA (SC) (NCT02506647)
  • 01 Dec 2015 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC) (NCT02506647)
  • 07 Aug 2015 Gan & Lee Pharmaceuticals plans a phase I trial for Type-1 diabetes mellitus in USA (NCT02506647)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top